Substituted indoles and pyrroles as RIP kinase inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9725452
SERIAL NO

14214360

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to heterocyclic compounds (e.g., compounds described by Formula (I)) and pharmaceutically acceptable salts thereof. The invention also features pharmaceutical compositions that include these compounds and their use in therapy for treating conditions in which necroptosis is likely to play a substantial role. The heterocyclic compounds described herein can also achieve improved activity and selectivity towards RIP1 and/or RIP3.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • PRESIDENT AND FELLOWS OF HARVARD COLLEGE;SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES;TUFTS UNIVERSITY;UNIVERSITY OF HOUSTON SYSTEM

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Cuny, Gregory D Houston, US 85 957
Degterev, Alexei Brookline, US 27 291
Yuan, Junying Newton, US 55 499

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Feb 8, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 8, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00